Ian T. Meredith - Feb 1, 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP Global Chief Med Officer
Signature
/s/ Vance R. Brown, Attorney-in-fact
Stock symbol
BSX
Transactions as of
Feb 1, 2022
Transactions value $
-$39,977
Form type
4
Date filed
2/2/2022, 03:37 PM
Previous filing
Jan 3, 2022
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +3.13K +10.94% $0.00 31.8K Feb 1, 2022 Direct F1
transaction BSX Common Stock Tax liability -$40K -919 -2.89% $43.50 30.8K Feb 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Deferred Stock Units Options Exercise $0 -3.13K -100% $0.00* 0 Feb 1, 2022 Common Stock 3.13K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.

Remarks:

meredithpoa.txt